These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 3677767)

  • 41. Pharmacokinetics of a 3 mg/kg body weight loading dose of gentamicin or tobramycin in critically ill patients.
    Chelluri L; Warren J; Jastremski MS
    Chest; 1989 Jun; 95(6):1295-7. PubMed ID: 2721269
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Drug therapy of bacterial infections in patients with kidney failure and hemodialysis].
    Yamasaku F
    Nihon Naika Gakkai Zasshi; 1990 Dec; 79(12):1646-52. PubMed ID: 2079588
    [No Abstract]   [Full Text] [Related]  

  • 43. Surgery-related infections: a challenge for the physician. Introduction.
    Nichols RL
    Surg Gynecol Obstet; 1990; 171 Suppl():9-10. PubMed ID: 2244296
    [No Abstract]   [Full Text] [Related]  

  • 44. Meta-analyses are no longer required for determining the efficacy of single daily dosing of aminoglycosides.
    Gilbert DN
    Clin Infect Dis; 1997 May; 24(5):816-9. PubMed ID: 9142774
    [No Abstract]   [Full Text] [Related]  

  • 45. Susceptibility of aerobic gram-negative bacilli to aminoglycosides. Effects of 45 months of amikacin as first-line aminoglycoside therapy.
    Saavedra S; Vera D; Ramírez-Ronda CH
    Am J Med; 1986 Jun; 80(6B):65-70. PubMed ID: 3014877
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [How to safely and effectively administer aminoglycoside antibiotics].
    Gomółka M; Niemczyk S
    Pol Merkur Lekarski; 2014 Apr; 36(214):225-8. PubMed ID: 24868892
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Once-daily dosing of aminoglycosides: review and recommendations for clinical practice.
    Freeman CD; Nicolau DP; Belliveau PP; Nightingale CH
    J Antimicrob Chemother; 1997 Jun; 39(6):677-86. PubMed ID: 9222035
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of loading doses on the time to adequate predicted beta-lactam concentrations in prolonged and continuous infusion dosing schemes.
    Rhodes NJ; MacVane SH; Kuti JL; Scheetz MH
    Clin Infect Dis; 2014 Sep; 59(6):905-7. PubMed ID: 24867788
    [No Abstract]   [Full Text] [Related]  

  • 49. Surveillance of aminoglycoside resistance. European data.
    Van Landuyt HW; Boelaert J; Glibert B; Gordts B; Verbruggen AM
    Am J Med; 1986 Jun; 80(6B):76-81. PubMed ID: 3089007
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Aminoglycoside nephrotoxicity: comparative assessment in critically ill patients.
    Plaut ME; Schentag JJ; Jusko WJ
    J Med; 1979; 10(4):257-66. PubMed ID: 294466
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Aminoglycoside therapy of gram-negative bacillary meningitis.
    Kaiser AB; McGee ZA
    N Engl J Med; 1975 Dec; 293(24):1215-20. PubMed ID: 1102982
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Antibiotic therapy for severe gram-negative infections].
    Vildé JL; Leport C
    Rev Prat; 1983 Jan; 33(3):117-24. PubMed ID: 6844820
    [No Abstract]   [Full Text] [Related]  

  • 53. Use of aminoglycosides in treatment of infections due to intracellular bacteria.
    Maurin M; Raoult D
    Antimicrob Agents Chemother; 2001 Nov; 45(11):2977-86. PubMed ID: 11600345
    [No Abstract]   [Full Text] [Related]  

  • 54. Clinical experience with aminoglycosides in dialysis-dependent patients: risk factors for mortality and reassessment of current dosing practices.
    Heintz BH; Thompson GR; Dager WE
    Ann Pharmacother; 2011 Nov; 45(11):1338-45. PubMed ID: 22010003
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [The effect of the pharmacodynamics of different classes of antibacterial preparations on their dosage regimens].
    Strachunskiĭ AS; Mukonin AA
    Antibiot Khimioter; 2000; 45(4):40-4. PubMed ID: 10851650
    [No Abstract]   [Full Text] [Related]  

  • 56. [Clinical evaluation of micronomicin for the treatment of postoperative infections in cancer patients].
    Ohmori K; Suzuki M; Endo S; Watanabe I; Endo S
    Jpn J Antibiot; 1983 Jul; 36(7):1593-8. PubMed ID: 6655802
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and safety of aminoglycosides once-a-day: experimental and clinical data.
    Tulkens PM
    Scand J Infect Dis Suppl; 1990; 74():249-57. PubMed ID: 2097713
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Aminoglycosides against carbapenem-resistant Enterobacteriaceae in the critically ill: the pitfalls of aminoglycoside susceptibility.
    Zavascki AP; Klee BO; Bulitta JB
    Expert Rev Anti Infect Ther; 2017 Jun; 15(6):519-526. PubMed ID: 28375030
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Preclinical and clinical evaluation of once-daily aminoglycoside chemotherapy.
    Periti P
    J Chemother; 1995 Aug; 7(4):311-37. PubMed ID: 8568543
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Suboptimal aminoglycoside dosing in critically ill patients.
    Rea RS; Capitano B; Bies R; Bigos KL; Smith R; Lee H
    Ther Drug Monit; 2008 Dec; 30(6):674-81. PubMed ID: 19057371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.